CNR1 and Parkinson disease: In the [18F]MK9470 study, the PET imaging was done on medication in the advanced PD groups, which might explain why they saw decreased CB1 availability only in substantia nigra, as we observed that the antiparkinsonian medication increases the CB1 availability in subjects with PD.